杜洛特格拉维尔药理动学的遗传变异以及与安全性和疗效结果的关系:系统性审查
Lisanne A H Bevers1, Rebecca L Jensen2, Andrew Owen2
1Department of Pharmacy, Radboudumc Research Institute for medical Innovation (RIMI), Radboud University Medical Center, Nijmegen, The Netherlands.
Pharmacogenomics
|December 19, 2024
概括
对多卢特格拉维尔 (DTG) 的药物基因组学 (PGx) 研究表明,遗传变异会影响药物暴露和潜在的副作用. 虽然PGx测试可能有助于理解,但目前的证据不支持其用于DTG治疗的常规临床使用.
科学领域:
- 药物基因组学 药物基因组学
- 艾滋病毒治疗药物 艾滋病治疗药物
- 抗病毒药物代谢 抗病毒药物代谢
背景情况:
- 多卢特格拉维尔 (DTG) 是一种关键的艾滋病毒治疗方法,但影响其疗效和毒性的遗传因素尚未完全理解.
- 药物暴露和临床结果的变化需要研究药物基因组学 (PGx) 的作用.
研究的目的:
- 系统地审查药物基因组学对多卢特格拉维尔 (DTG) 暴露,疗效和毒性的影响.
- 为了确定影响DTG药理动力学和艾滋病毒感染者的药理动力学的遗传变异.
主要方法:
- 在2023年11月14日之前发表的原始研究文章的系统审查.
- 纳入标准侧重于涉及艾滋病毒感染者的研究,药物基因组学数据和药物动力学或药物动力学数据.
主要成果:
- 从711个记录中包含了10篇文章,分析了UGT1A1,ABCB1,ABCG2和NR1I2.2.等基因.
- 一种SLC22A2的变异与神经精神病学不良事件的风险增加有关,这表明药理动力学可变性.
结论:
- 药物基因组学测试可能有助于解释杜洛特格拉维尔 (DTG) 的药物动力学变异性,特别是在治疗药物监测 (TDM) 时.
- 目前的证据不足以为DTG进行常规的临床PGx测试.
- 进一步的PGx研究对于了解特定患者群体中无法解释的个体间药理动力学变异至关重要.
关键词:
多卢特格拉维尔 (Dolutegravir) 是一种药物.艾滋病病毒 艾滋病病毒 艾滋病病毒抗逆转录病毒药物使用药理动力学是药理动力学的一个方面.药物基因组学 药物基因组学药物动力学 药物动力学更多相关视频
相关概念视频
Analysis of Population Pharmacokinetic Data
224
Analysis of population pharmacokinetic data involves studying the behavior of drugs within diverse populations to understand their pharmacokinetic parameters. Traditional pharmacokinetic methods typically involve collecting samples from a few individuals and estimating these parameters. While these methods are commonly used, they have limitations in capturing the variability in drug response among individuals or heterogeneous populations. Population pharmacokinetics is employed to address these...
224
Nonlinear Pharmacokinetics: Dependence of Elimination Half-Life and Dose Clearance
80
The elimination half-life and drug clearance of drugs following nonlinear kinetics can vary with dosage. The Michaelis-Menten parameters and drug concentration influence these factors. As the dose increases, the elimination half-life tends to lengthen, resulting in a reduction in clearance and a disproportionately larger area under the curve. The total clearance can be derived from the Michaelis-Menten equation for drugs following a one-compartment model.
A study on guinea pigs examined the...
A study on guinea pigs examined the...
80
Mutation, Gene Flow, and Genetic Drift
58.0K
In a population that is not at Hardy-Weinberg equilibrium, the frequency of alleles changes over time. Therefore, any deviations from the five conditions of Hardy-Weinberg equilibrium can alter the genetic variation of a given population. Conditions that change the genetic variability of a population include mutations, natural selection, non-random mating, gene flow, and genetic drift (small population size).
58.0K
Volume of Distribution
108
The apparent volume of distribution (Vd) is a crucial pharmacokinetic parameter representing the hypothetical body fluid volume into which a drug disperses. It is calculated based on the total amount of drug in the body (estimated from the administered dose and bioavailability) divided by the plasma drug concentration. The total amount of drug in the body does not directly refer to the dose given but is derived by accounting for absorption, distribution, metabolism, and excretion processes.
108
Bioequivalence: Overview
921
Pharmaceutical equivalents, by definition, are drug products with the same active ingredient in the same quantities, encapsulated in identical dosage forms, and intended for the same administration routes. These pharmaceutical equivalents are deemed bioequivalent if the bioavailability of the active entity in the drug preparations is similar. Moreover, pharmaceutical equivalents demonstrating bioequivalence are also regarded as therapeutically equivalent. This means that when used as directed,...
921
Pharmacovigilance
773
Post-marketing surveillance is a critical component of pharmaceutical regulation, often uncovering unanticipated adverse drug reactions (ADRs) once a drug is widely used over an extended period.
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
773


